DK1585513T3 - Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi - Google Patents

Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi

Info

Publication number
DK1585513T3
DK1585513T3 DK03812244T DK03812244T DK1585513T3 DK 1585513 T3 DK1585513 T3 DK 1585513T3 DK 03812244 T DK03812244 T DK 03812244T DK 03812244 T DK03812244 T DK 03812244T DK 1585513 T3 DK1585513 T3 DK 1585513T3
Authority
DK
Denmark
Prior art keywords
lipodystrophy
treatment
active substance
docosahexaenoic acid
medicament
Prior art date
Application number
DK03812244T
Other languages
Danish (da)
English (en)
Inventor
Pedrol Juan Carlos Domingo
Pedrol Pere Domingo
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Application granted granted Critical
Publication of DK1585513T3 publication Critical patent/DK1585513T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK03812244T 2002-12-05 2003-12-01 Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi DK1585513T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.

Publications (1)

Publication Number Publication Date
DK1585513T3 true DK1585513T3 (da) 2006-09-18

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03812244T DK1585513T3 (da) 2002-12-05 2003-12-01 Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi

Country Status (24)

Country Link
US (1) US8202906B2 (es)
EP (1) EP1585513B1 (es)
JP (1) JP2006511514A (es)
KR (1) KR100906086B1 (es)
CN (1) CN100355421C (es)
AT (1) ATE326959T1 (es)
AU (1) AU2003302679B2 (es)
BR (1) BR0316973A (es)
CA (1) CA2506993C (es)
CY (1) CY1105205T1 (es)
DE (1) DE60305534T2 (es)
DK (1) DK1585513T3 (es)
EA (1) EA009711B1 (es)
ES (2) ES2209658B1 (es)
IL (1) IL168766A (es)
IS (1) IS2384B (es)
MX (1) MXPA05005911A (es)
NO (1) NO20052960L (es)
NZ (1) NZ540262A (es)
PL (1) PL377563A1 (es)
PT (1) PT1585513E (es)
UA (1) UA79650C2 (es)
WO (1) WO2004050077A1 (es)
ZA (1) ZA200503872B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2711569C (en) * 2008-01-03 2017-08-01 Universite De La Mediterannee, Aix-Marseille Ii Composition and processes for use in an anti-hiv treatment
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
ATE384518T1 (de) * 2000-01-31 2008-02-15 Haerting S A Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
IS2384B (is) 2008-07-15
BR0316973A (pt) 2005-10-25
ATE326959T1 (de) 2006-06-15
EP1585513A1 (en) 2005-10-19
ES2265607T3 (es) 2007-02-16
NZ540262A (en) 2006-11-30
EA200500765A1 (ru) 2005-12-29
EP1585513B1 (en) 2006-05-24
AU2003302679A1 (en) 2004-06-23
KR100906086B1 (ko) 2009-07-06
PT1585513E (pt) 2006-10-31
WO2004050077A1 (en) 2004-06-17
US20060178436A1 (en) 2006-08-10
CY1105205T1 (el) 2010-03-03
PL377563A1 (pl) 2006-02-06
ES2209658A1 (es) 2004-06-16
CN1720039A (zh) 2006-01-11
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
AU2003302679B2 (en) 2009-01-15
DE60305534D1 (de) 2006-06-29
EA009711B1 (ru) 2008-02-28
ZA200503872B (en) 2006-08-30
DE60305534T2 (de) 2007-05-16
IL168766A (en) 2009-11-18
CN100355421C (zh) 2007-12-19
CA2506993C (en) 2010-04-13
KR20050085313A (ko) 2005-08-29
US8202906B2 (en) 2012-06-19
NO20052960L (no) 2005-06-16
JP2006511514A (ja) 2006-04-06
CA2506993A1 (en) 2004-06-17
MXPA05005911A (es) 2005-08-29
UA79650C2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
IS2384B (is) Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
EA201270615A1 (ru) Противогрибковый препарат, содержащий грибковый организм
BRPI0720500A8 (pt) Preparação líquida transdérmica
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
SE0950392L (sv) Sammansättning för behandling av hudåkommor
DK1677806T3 (da) Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre
DK1343472T3 (da) Thixotropisk næsespray
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
DK1251850T3 (da) Anvendelse af et kombinationspræparat i cancerbehandling
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
EA202092077A1 (ru) Местные составы, содержащие стронций и метилсульфонилметан (мсм), и способы лечения
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
ECSP045244A (es) Composiciones farmaceuticas
ECSP045056A (es) Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion
RU2010144554A (ru) Средство для предотвращения и/или лечения сосудистых заболеваний
UA123399U (uk) Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components